Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Thyroid cancer: pathogenesis and targeted therapy.

Liebner DA, Shah MH.

Ther Adv Endocrinol Metab. 2011 Oct;2(5):173-95. doi: 10.1177/2042018811419889.

2.

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.

Deshpande H, Roman S, Thumar J, Sosa JA.

Clin Med Insights Oncol. 2011;5:213-21. doi: 10.4137/CMO.S6197. Epub 2011 Jul 20.

3.

[Current progress and management in molecular targeted therapy for advanced thyroid cancer].

Okamura R, Sugitani I.

Gan To Kagaku Ryoho. 2014 Feb;41(2):148-52. Japanese.

PMID:
24743192
4.

Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.

Sathornsumetee S, Rich JN.

Drugs Today (Barc). 2006 Oct;42(10):657-70. Review.

PMID:
17136225
5.

Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.

Almeida MQ, Hoff AO.

Curr Opin Oncol. 2012 May;24(3):229-34. doi: 10.1097/CCO.0b013e328351c71a. Review.

PMID:
22343387
6.

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F.

Oncologist. 2009 Apr;14(4):378-90. doi: 10.1634/theoncologist.2008-0261. Epub 2009 Apr 6. Review.

7.

Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.

Pennell NA, Lynch TJ Jr.

Oncologist. 2009 Apr;14(4):399-411. doi: 10.1634/theoncologist.2008-0276. Epub 2009 Apr 8. Review.

8.

Vandetanib therapy in medullary thyroid cancer.

Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D.

Drugs Today (Barc). 2012 Nov;48(11):723-33. doi: 10.1358/dot.2012.48.11.1867323. Review.

PMID:
23170308
9.

Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.

Deshpande HA, Gettinger SN, Sosa JA.

Curr Opin Oncol. 2008 Jan;20(1):19-24. Review.

PMID:
18043252
10.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
11.

An update on clinical trials of targeted therapies in thyroid cancer.

Haraldsdottir S, Shah MH.

Curr Opin Oncol. 2014 Jan;26(1):36-44. doi: 10.1097/CCO.0000000000000029. Review.

PMID:
24240178
12.

Promising molecular targeted therapies in breast cancer.

Munagala R, Aqil F, Gupta RC.

Indian J Pharmacol. 2011 May;43(3):236-45. doi: 10.4103/0253-7613.81497.

13.

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G.

Clin Cancer Res. 2008 Aug 15;14(16):5069-80. doi: 10.1158/1078-0432.CCR-07-4905. Epub 2008 Aug 11.

14.

[Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].

Malouf G, Baudin E, Soria JC, Schlumberger M.

Bull Cancer. 2009 Jan;96(1):95-101. doi: 10.1684/bdc.2008.0798. Review. French.

PMID:
19211364
15.

New molecular targeted therapies in thyroid cancer.

Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F.

Anticancer Drugs. 2006 Sep;17(8):869-79. Review.

PMID:
16940797
16.

New targeted therapies for thyroid cancer.

Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P.

Curr Genomics. 2011 Dec;12(8):626-31. doi: 10.2174/138920211798120808.

17.

RET TKI: potential role in thyroid cancers.

Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, Ferri C.

Curr Oncol Rep. 2012 Apr;14(2):97-104. doi: 10.1007/s11912-012-0217-0. Review.

PMID:
22286373
18.

Medullary thyroid cancer: therapeutic targets and molecular markers.

Ball DW.

Curr Opin Oncol. 2007 Jan;19(1):18-23. Review.

PMID:
17133107
19.

Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Giunti S, Antonelli A, Amorosi A, Santarpia L.

Int J Endocrinol. 2013;2013:803171. doi: 10.1155/2013/803171. Epub 2013 Feb 21.

20.

Vandetanib and the management of advanced medullary thyroid cancer.

Campbell MJ, Seib CD, Gosnell J.

Curr Opin Oncol. 2013 Jan;25(1):39-43. doi: 10.1097/CCO.0b013e32835a42b9. Review.

PMID:
23202050
Items per page

Supplemental Content

Write to the Help Desk